Management of Penile Ulcers with Positive VDRL

Initial Diagnostic Approach

The Centers for Disease Control and Prevention recommends darkfield microscopy or direct fluorescent antibody testing of the ulcer exudate as the definitive diagnostic method for early syphilis when lesions are present 1, 3
The Centers for Disease Control and Prevention suggests performing a quantitative nontreponemal test (VDRL or RPR) to document the baseline titer, which is essential for monitoring treatment response 4, 3
The Centers for Disease Control and Prevention advises treponemal test confirmation (FTA-ABS or TP-PA) to confirm true syphilis infection versus false-positive VDRL 3, 5
The Centers for Disease Control and Prevention recommends HIV testing for all patients with syphilis, as HIV coinfection affects management and follow-up 2, 6
The Centers for Disease Control and Prevention suggests evaluation for other sexually transmitted infections, including HSV culture or antigen testing and consideration of chancroid (Haemophilus ducreyi) if in endemic areas 1

The Centers for Disease Control and Prevention recommends benzathine penicillin G 2.4 million units IM as a single dose for primary syphilis 1, 2, 5
The Centers for Disease Control and Prevention advises performing a lumbar puncture for CSF examination in patients with neurologic symptoms or ocular manifestations 2, 6
The Centers for Disease Control and Prevention recommends aqueous crystalline penicillin G 18-24 million units per day IV for 10-14 days if neurosyphilis is confirmed 2, 6
The Centers for Disease Control and Prevention suggests doxycycline 100 mg orally twice daily for 14 days as an acceptable alternative for non-pregnant patients with early syphilis and penicillin allergy 2, 5
The Centers for Disease Control and Prevention recommends penicillin desensitization for pregnant patients or neurosyphilis, as penicillin is the only proven effective treatment 4, 2, 6

The Centers for Disease Control and Prevention recommends clinical and serologic evaluation at 6 and 12 months post-treatment using quantitative nontreponemal tests (same method, same laboratory) 2, 5
The Centers for Disease Control and Prevention defines treatment success as a fourfold decline in nontreponemal titer within 6-12 months 4, 3, 5
The Centers for Disease Control and Prevention advises more frequent monitoring at 3-month intervals instead of 6-month intervals for HIV-positive patients 2, 5

The Centers for Disease Control and Prevention warns against delaying treatment waiting for darkfield results, and recommends treating empirically for syphilis if clinical suspicion is high and diagnostic capabilities are limited 1
The Centers for Disease Control and Prevention advises against using treponemal test titers to monitor treatment response, as these remain positive for life in most patients regardless of cure 4, 3, 5
The Centers for Disease Control and Prevention recommends against comparing VDRL and RPR titers directly, and suggests using the same test method throughout follow-up 4, 3
The Centers for Disease Control and Prevention warns against assuming treatment failure with persistent low titers, as some patients remain "serofast" with stable low titers despite adequate treatment 5

The Centers for Disease Control and Prevention recommends evaluating and treating all sexual contacts within the past 90 days (for primary syphilis) presumptively 1, 4
The Centers for Disease Control and Prevention notes that sexual transmission occurs only when mucocutaneous lesions are present, which is uncommon after the first year of infection 4

The Centers for Disease Control and Prevention warns patients about possible acute febrile reaction within 24 hours of treatment, characterized by fever, headache, and myalgia 4
The Centers for Disease Control and Prevention notes that this reaction is common in early syphilis and does not indicate treatment failure 4
The Centers for Disease Control and Prevention suggests that antipyretics may be recommended, though no proven prevention methods exist 4